Gilead Sciences, Inc.
SOLID FORMS OF AN HIV PROTEASE INHIBITOR

Abstract:

The present disclosure relates to pharmaceutically acceptable salts and crystalline forms thereof, of a compound which is (S)-2-(4-chloro-3-(1-(difluoromethyl)-1H-1,2,4-triazol-5-yl)phenyl)-2-((R- )-4-(4-(2-cyclopropyl-2H-1,2,3-triazol-4-yl)phenyl)-2-imino-5-oxo-4-(3,3,3- -trifluoro-2,2-dimethylpropyl)imidazolidin-1-yl)ethyl (1- (difluoromethyl)cyclopropyl)carbamate, which is useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.